In 2011, the US Food and Drug Administration (FDA) announced a mandate to limit acetaminophen (paracetamol) to 325 mg/tablet in combination acetaminophen and opioid medications, with manufacturer compliance required by early 2014. In this podcast, JAMA Deputy Editor Mary M. McDermott, MD, interviews Jayme E. Locke, MD, MPH, and Babak J. Orandi, MD, PhD, about their JAMA study describing results of the FDA announcement on subsequent rates of hospitalizations for acute liver failure due to toxicity from acetaminophen-containing opioid drugs. Related Content:

• Association of FDA Mandate Limiting Acetaminophen (Paracetamol) in Prescription Combination Opioid Products and Subsequent Hospitalizations and Acute Liver Failure
• Moving the Needle to Reduce Acetaminophen (Paracetamol) Hepatotoxicity
• Acetaminophen (Paracetamol) and Acute Liver Failure